



## Haemonetics Announces Definitive Agreement to Acquire Global Med Technologies Inc.

Haemonetics Corporation (NYSE: HAE) and Global Med Technologies, Inc. (OTCBB: GLOB) announced a definitive agreement under which Haemonetics will acquire Global Med for approximately \$60 million in a cash tender offer. St. Charles Capital acted as exclusive financial advisor to Global Med Technologies in this transaction.



**GLOBAL MED**  
TECHNOLOGIES™

Global Med Technologies, Inc. (OTCBB: GLOB) is an international healthcare information technology company which markets a breadth of software solutions and services that span the blood supply continuum, from blood collection to the hospital transfusion center to the patient care environment. As a leading provider of blood and laboratory systems and services, Global Med's products are deployed in 20 countries and serve over 2,100 transfusion centers, blood banks and laboratory sites.

**HAEMONETICS®**  
*THE Blood Management Company*

Headquartered in Braintree, Massachusetts, Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. As a global leader in blood management solutions, Haemonetics helps plasma fractionators, hospitals and blood collectors to improve clinical care and lower costs by optimizing the collection, processing, and use of scarce blood resources. Haemonetics also markets information technology platforms and consulting services to help manage the blood supply chain and improve blood management practices.

Michael I. Ruxin, M.D., Chairman and CEO of Global Med Technologies said, "The integration of our two companies is very exciting. We share a common strategy to provide blood management tools to hospitals and blood centers that improve patient care and reduce costs. In the blood management arena, Global Med brings a broad-based information technology platform offering that spans the blood supply chain, while Haemonetics brings devices, software, and consulting services for optimal blood management. This merger is especially advantageous to our customers, as well as the blood center and hospital transfusion industry because we believe our combined organizations can provide expanded access to new technologies and innovative products while leveraging the efficiencies of a larger organization."

**St. Charles Capital**, based in Denver, Colorado, provides expertise in mergers and acquisitions, raising private capital, and financial advisory services for middle-market companies nationwide.

For more information, please contact the following:

Douglas S. Robinson, Managing Director, [drobenson@stcharlescapital.com](mailto:drobenson@stcharlescapital.com)

Jon N. Pardew, Managing Director, [jpardew@stcharlescapital.com](mailto:jpardew@stcharlescapital.com)

Michael C. Huguelet, Associate, [mhuguelet@stcharlescapital.com](mailto:mhuguelet@stcharlescapital.com)